Sequenom, Inc. (NASDAQ: SQNM), a life sciences company committed to enabling healthier lives through the development of innovative products and services, today announced that it has entered into a clinical collaboration with University Medical Center Hamburg-Eppendorf (UKE) in Germany. UKE and Sequenom will collaborate to profile circulating cell-free tumor DNA in blood to monitor response to treatment in later stage colorectal cancer patients. This technology has the potential to overcome the challenges and limitations associated with current methods such as imaging, colonoscopy, and invasive biopsies.
Sequenom Collaborates With University Medical Center Hamburg-Eppendorf To Evaluate Clinical Utility Of Liquid Biopsy In Colorectal Cancer
Sony DADC BioSciences and FIANOSTICS GmbH Announce Collaboration in Development of a Novel Assay Platform
In course of the Basel Life Science Week 2015 Sony DADC BioSciences and FIANOSTICS GmbH announced a collaboration on highly sensitive and rapid fluorescence immunoassays using a novel polymer/metal hybrid for the use in metal-enhanced fluorescence (MEF). Sony DADC uses its well established manufacturing processes derived from Blu-ray disc production.
Ventana Medical Systems, Inc. and Astellas Pharma Join Forces to Leverage Novel Companion Diagnostic Tests for Targeted Cancer Treatments
Ventana Medical Systems, Inc. (Ventana), a member of the Roche Group, recently announced it has entered into master collaboration agreement with Astellas Pharma Inc., an R&D-driven global pharmaceutical company headquartered in Japan, to develop novel automated tissue diagnostics in support of therapeutic compounds in development.
GATC Biotech, provider of innovative, high quality DNA and RNA sequencing solutions to the pharmaceutical and diagnostics markets, recently announced that it has signed a commercial agreement with Molecular Health. Under this agreement, GATC Biotech will make TreatmentMAP available to patients worldwide. The initial plans of the commercial collaboration are to market and support Molecular Health’s state-of-the-art system for tumour profiling.
Children’s Hospital Colorado and SomaLogic, Inc., recently announced that they have entered into a collaborative agreement to discover protein biomarkers and use those biomarkers to develop laboratory tests to improve the diagnosis and management of childhood diseases. The discovery and development work will be done using SomaLogic’s novel proteomics SOMAscan™ assay, which can measure more than a thousand proteins in a small amount of blood or other biological samples. This innovative collaboration is being entered into as a result of successful initial exploratory research done by the two organizations.